**Supplementary Results**

**eTables**

| eTable 1. Pattern-Mixture Model on SOWS-Gossop Score From Days 1 to 7 Inclusive (Double‑Blind Phase, mITT Population) | | | | | |
| --- | --- | --- | --- | --- | --- |
| Day / Treatment | Overall Geometric Mean\* | LS Mean† | Difference vs Placebo | Two-Sided 95% CI for Mean Difference | *P* Value |
| **Overall (Primary Endpoint)** | | | | | |
| Placebo | 5.23 | 1.83 |  |  |  |
| Lofexidine 2.16 mg/day | 4.07 | 1.62 | –0.21 | (–0.37, −0.04) | .0166 |
| Lofexidine 2.88 mg/day | 3.80 | 1.57 | –0.26 | (–0.44, −0.09) | .0033 |
| **Day 1** |  |  |  |  |  |
| Placebo | 6.93 | 2.07 |  |  |  |
| Lofexidine 2.16 mg/day | 5.73 | 1.91 | –0.16 | (–0.30, −0.03) | .0168 |
| Lofexidine 2.88 mg/day | 5.11 | 1.81 | –0.26 | (–0.41, −0.11) | <.001 |
| **Day 2** |  |  |  |  |  |
| Placebo | 11.42 | 2.52 |  |  |  |
| Lofexidine 2.16 mg/day | 8.29 | 2.23 | –0.29 | (–0.45, −0.13) | <.001 |
| Lofexidine 2.88 mg/day | 7.82 | 2.18 | –0.34 | (–0.52, −0.16) | <.001 |
| **Day 3** |  |  |  |  |  |
| Placebo | 8.86 | 2.29 |  |  |  |
| Lofexidine 2.16 mg/day | 6.56 | 2.02 | –0.27 | (–0.46, −0.07) | .009 |
| Lofexidine 2.88 mg/day | 5.92 | 1.93 | –0.35 | (–0.56, −0.15) | <.001 |
| **Day 4** |  |  |  |  |  |
| Placebo | 6.75 | 2.05 |  |  |  |
| Lofexidine 2.16 mg/day | 4.57 | 1.72 | –0.33 | (–0.57, −0.09) | .006 |
| Lofexidine 2.88 mg/day | 4.16 | 1.64 | –0.41 | (–0.64, −0.17) | <.001 |
| **Day 5** |  |  |  |  |  |
| Placebo | 4.82 | 1.76 |  |  |  |
| Lofexidine 2.16 mg/day | 3.38 | 1.48 | –0.28 | (–0.52, −0.05) | .02 |
| Lofexidine 2.88 mg/day | 3.32 | 1.46 | –0.30 | (–0.54, −0.05) | .02 |
| **Day 6** |  |  |  |  |  |
| Placebo | 2.70 | 1.31 |  |  |  |
| Lofexidine 2.16 mg/day | 2.35 | 1.21 | –0.10 | (–0.41, 0.22) | .53 |
| Lofexidine 2.88 mg/day | 2.24 | 1.18 | –0.13 | (–0.45, 0.19) | .42 |
| **(Continued)**  **Day 7** |  |  |  |  |  |
| Placebo | 1.26 | 0.81 |  |  |  |
| Lofexidine 2.16 mg/day | 1.24 | 0.81 | –0.01 | (–0.33, 0.31) | .96 |
| Lofexidine 2.88 mg/day | 1.16 | 0.77 | –0.04 | (–0.37, 0.28) | .80 |
|  | | | | | |

\*The geometric mean SOWS-Gossop score on each study day is the back-transformed LS mean estimate based on log-transformed data.

†Least squares means from a pattern-mixture model using an unstructured covariance model and degrees of freedom (df) associated with the error term computed using the Kenward-Rogers method. The log transformation is log (SOWS-Gossop score + pi1). *P* values are from inference on the log scale.

The score ranges from 0-30 with a lower score being favorable.

|  |
| --- |
| LS, least squares; mITT, modified intent-to-treat; SOWS-Gossop, Short Opiate Withdrawal Scale of Gossop. |